By Drug Target Review2024-04-16T12:30:17
The new findings could result in a clinical trial to assess whether a one-year course of treatment could stop brain tumours.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2024-01-26T13:22:42
Sponsored by bit.bio
2023-07-04T10:05:58
Sponsored by Revvity
2023-09-27T10:36:50
Sponsored by NanoTemper Technologies
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2025-09-18T12:00:00
Sponsored by Benchling
Site powered by Webvision Cloud